Boston, Mass., March 24, 2017– The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness of crisaborole (Eucrisa™, Pfizer, Inc.) for treatment of mild-to-moderate atopic dermatitis in adults and children, and the clinical effectiveness and value of and dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) for treatment of moderate-to-severe atopic dermatitis in adults. The report, as well as accompanying draft voting questions, is now open to public comment for four weeks.
ICER is committed to engaging with all stakeholders in a thorough and transparent manner. Before completing this Draft Evidence Report, ICER reached out to key stakeholders, including patient groups, clinical experts, and the manufacturers of the drugs to engage them in the process. ICER also accepted public comments on a Draft Scoping Document prior to conducting the review. The current draft report incorporates input received from patients, clinicians, manufacturers, and other stakeholders during each of these opportunities for engagement.
The Draft Evidence Report, as well as the accompanying voting questions, will be open to public comment until April 21, 2017 at 5PM CT. All stakeholders are invited to submit formal comments by email to firstname.lastname@example.org. Guidelines for submitting public comments, including formatting specifications, are available on the ICER website. ICER will review all comments received and incorporate any necessary changes in the Evidence Report and revised voting questions that will be posted on or about May 12, 2017. All comments will be posted publicly along with the Evidence Report.
The Evidence Report, which will include value-based price benchmarks for the treatments under review, will be the subject of a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) on May 25, 2017 in Chicago, IL. During the meeting, the independent Council will vote on key questions raised in the report, and an expert policy roundtable will discuss recommendations to apply the evidence to policy and practice.
During the public meeting, there will be a limited amount of time available for interested stakeholders to make an oral comment on the report. Beginning today, requests to submit oral comment are being accepted. All requests must be emailed to email@example.com by 5PM CT on April 21, 2017. For more information about registering for oral comment, please visit our website.Register now to attend the meeting in person, or watch the live webcast.Visit ICER’s website for more information on our methods for public engagement.